EA201890106A1 - Способы лечения аутоиммунных и аллоиммунных расстройств - Google Patents

Способы лечения аутоиммунных и аллоиммунных расстройств

Info

Publication number
EA201890106A1
EA201890106A1 EA201890106A EA201890106A EA201890106A1 EA 201890106 A1 EA201890106 A1 EA 201890106A1 EA 201890106 A EA201890106 A EA 201890106A EA 201890106 A EA201890106 A EA 201890106A EA 201890106 A1 EA201890106 A1 EA 201890106A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
autoimmune
treatment
individual
alloimmune
Prior art date
Application number
EA201890106A
Other languages
English (en)
Other versions
EA038567B1 (ru
Inventor
Грэм Пэрри
Павел А. Никитин
Сандип Пэникер
Original Assignee
БИОВЕРАТИВ ЮЭсЭй ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by БИОВЕРАТИВ ЮЭсЭй ИНК. filed Critical БИОВЕРАТИВ ЮЭсЭй ИНК.
Publication of EA201890106A1 publication Critical patent/EA201890106A1/ru
Publication of EA038567B1 publication Critical patent/EA038567B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В данном описании предложены способы лечения аллоиммунного или аутоиммунного расстройства у индивидуума; включающие введение индивидууму эффективного количества антитела, специфичного для компонента комплемента C1s. В данном описании предложен способ контроля эффективности способа лечения пациента; этот способ включает определение уровня аутоантитела или аллоантитела в биологическом образце, полученном от индивидуума.
EA201890106A 2015-06-26 2016-06-23 Способы лечения аутоиммунных и аллоиммунных расстройств EA038567B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185362P 2015-06-26 2015-06-26
PCT/US2016/039087 WO2016210172A1 (en) 2015-06-26 2016-06-23 Methods of treating autoimmune and alloimmune disorders

Publications (2)

Publication Number Publication Date
EA201890106A1 true EA201890106A1 (ru) 2018-05-31
EA038567B1 EA038567B1 (ru) 2021-09-15

Family

ID=57585852

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890106A EA038567B1 (ru) 2015-06-26 2016-06-23 Способы лечения аутоиммунных и аллоиммунных расстройств

Country Status (13)

Country Link
US (2) US20180169240A1 (ru)
EP (1) EP3313417A4 (ru)
JP (1) JP6963509B2 (ru)
KR (1) KR20180020296A (ru)
CN (1) CN108348600A (ru)
AU (2) AU2016282782A1 (ru)
BR (1) BR112017027578A2 (ru)
CA (1) CA2990662A1 (ru)
EA (1) EA038567B1 (ru)
HK (1) HK1254030A1 (ru)
IL (1) IL256424B1 (ru)
MX (2) MX2017016835A (ru)
WO (1) WO2016210172A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889170C (en) 2012-10-25 2021-09-07 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
RS63212B1 (sr) 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene
EP4212175A1 (en) 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
MX2018013222A (es) 2016-04-29 2019-04-22 Pfizer Anticuerpos de interferon beta y usos de los mismos.
US20240092889A1 (en) * 2019-10-16 2024-03-21 Chugai Seiyaku Kabushiki Kaisha An antibody, a pharmaceutical composition, and a method
US11958899B2 (en) 2021-07-13 2024-04-16 Mabwell Therapeutics Inc. Anti-C1s antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013945A1 (en) * 1999-08-23 2001-03-01 Biocrystal Ltd. Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
US20040115194A1 (en) * 2002-09-06 2004-06-17 Yi Wang Method of treatment of asthma using antibodies to complement component C5
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
JP5739326B2 (ja) * 2008-04-25 2015-06-24 ザイモジェネティクス， インコーポレイテッド Ｂ細胞上でのｂｃｍａタンパク発現レベル及び診断法における使用
RU2012102021A (ru) * 2009-06-23 2013-07-27 Алексион Фармасьютикалз, Инк. Биспецифические антитела, которые связываются с белками комплемента
CA2889170C (en) * 2012-10-25 2021-09-07 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
RS63212B1 (sr) * 2012-11-02 2022-06-30 Bioverativ Usa Inc Antikomplementna c1s antitela i njihove primene

Also Published As

Publication number Publication date
IL256424A (en) 2018-02-28
EP3313417A1 (en) 2018-05-02
BR112017027578A2 (pt) 2018-08-28
CN108348600A (zh) 2018-07-31
MX2023002021A (es) 2023-03-15
MX2017016835A (es) 2018-08-01
JP6963509B2 (ja) 2021-11-10
CA2990662A1 (en) 2016-12-29
AU2022215307A1 (en) 2022-09-08
IL256424B1 (en) 2024-05-01
AU2016282782A1 (en) 2018-01-18
EP3313417A4 (en) 2019-06-12
JP2018526330A (ja) 2018-09-13
KR20180020296A (ko) 2018-02-27
EA038567B1 (ru) 2021-09-15
WO2016210172A1 (en) 2016-12-29
HK1254030A1 (zh) 2019-07-12
US20220249664A1 (en) 2022-08-11
US20180169240A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
EA201890106A1 (ru) Способы лечения аутоиммунных и аллоиммунных расстройств
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201990346A1 (ru) Антитела к gprc5d, биспецифические антигенсвязывающие молекулы, которые связывают gprc5d и cd3, и их применение
EA201691683A1 (ru) Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
EA201791775A1 (ru) Цистеиновая протеаза
MX2017005751A (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
EA201790405A1 (ru) Композиции и способы лечения метаболических расстройств
EA201790530A1 (ru) Агенты, связывающиеся с cd123, и виды их применения
EA201690969A1 (ru) Способы и композиции для лечения связанных со старением состояний
EA201590849A1 (ru) Композиции, способы и применения для лечения диабета и связанных состояний посредством контроля уровня глюкозы крови
MX2017004646A (es) Aparato y metodo de tratamiento de sustrato de piel de animal.
EA201591417A1 (ru) Новый способ диагностики депрессии и мониторинга эффективности терапии
EA201790192A1 (ru) СПОСОБ СНИЖЕНИЯ Fc-РЕЦЕПТОРНОГО СВЯЗЫВАНИЯ МОЛЕКУЛ СЫВОРОТОЧНОГО IgG У СУБЪЕКТА
MX2013012284A (es) Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
EA201790439A1 (ru) Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами
MA42657A (fr) Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
EA201992248A1 (ru) АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
EA202191666A1 (ru) Антитела к il-27 и их применение
MX2017016337A (es) Tratamiento de carcinoma de linea media nut.